These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 36754139)

  • 21. Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity.
    Huang Y; Huang C; Zhang Q; Shen T; Sun J
    BMC Neurol; 2022 Jan; 22(1):39. PubMed ID: 35086487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment.
    Asken BM; VandeVrede L; Rojas JC; Fonseca C; Staffaroni AM; Elahi FM; Lindbergh CA; Apple AC; You M; Weiner-Light S; Brathaban N; Fernandes N; Boxer AL; Miller BL; Rosen HJ; Kramer JH; Casaletto KB
    J Int Neuropsychol Soc; 2022 Jul; 28(6):588-599. PubMed ID: 34158138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma neurofilament light as a promising biomarker in neuronal intranuclear inclusion disease.
    Liu M; Zhu Y; Yuan Y; Wang Y; Liu X; Li L; Gao Y; Yan H; Liu R; Cheng L; Yuan J; Wang Q; Li S; Liu Y; Wang Y; Shi C; Xu Y; Yang J
    J Neurol; 2024 Apr; 271(4):2042-2052. PubMed ID: 38189920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis.
    Lee HL; Seok JM; Chung YH; Min JH; Baek SH; Kim SM; Sohn E; Kim J; Kang SY; Hong YH; Shin HY; Cho JY; Oh J; Lee SS; Kim S; Kim SH; Kim HJ; Kim BJ; Kim BJ
    Mult Scler Relat Disord; 2023 Nov; 79():104957. PubMed ID: 37688927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between plasma NFL and disease progression in Parkinson's disease: a prospective cohort study.
    Ou R; Liu K; Lin J; Yang T; Xiao Y; Wei Q; Hou Y; Li C; Zhang L; Jiang Z; Zhao B; Chen X; Song W; Wu Y; Shang H
    J Neurol; 2024 Apr; 271(4):1837-1843. PubMed ID: 38063869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
    Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J
    Alzheimers Res Ther; 2024 Jul; 16(1):165. PubMed ID: 39054505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
    Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
    Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurofilament Light Chain and Glial Fibrillary Acidic Protein as early prognostic biomarkers after out-of-hospital cardiac arrest.
    Klitholm M; Jeppesen AN; Christensen S; Parkner T; Tybirk L; Kirkegaard H; Sandfeld-Paulsen B; Grejs AM
    Resuscitation; 2023 Dec; 193():109983. PubMed ID: 37778613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Diagnostic Biomarkers in Autism Spectrum Disorders: A Preliminary Study.
    Simone M; De Giacomo A; Palumbi R; Palazzo C; Lucisano G; Pompamea F; Micella S; Pascali M; Gabellone A; Marzulli L; Giordano P; Gargano CD; Margari L; Frigeri A; Ruggieri M
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Lerche S; Wurster I; Röben B; Zimmermann M; Machetanz G; Wiethoff S; Dehnert M; Rietschel L; Riebenbauer B; Deuschle C; Stransky E; Lieplt-Scarfone I; Gasser T; Brockmann K
    Mov Disord; 2020 Jul; 35(7):1138-1144. PubMed ID: 32445500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
    Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
    Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
    Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
    Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
    Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia.
    Ingannato A; Bagnoli S; Mazzeo S; Giacomucci G; Bessi V; Ferrari C; Sorbi S; Nacmias B
    Front Endocrinol (Lausanne); 2024; 15():1375302. PubMed ID: 38654932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric reference intervals for serum neurofilament light and glial fibrillary acidic protein using the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) cohort.
    Stukas S; Cooper J; Higgins V; Holmes D; Adeli K; Wellington CL
    Clin Chem Lab Med; 2024 Mar; 62(4):698-705. PubMed ID: 37882772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum glial fibrillary acidic protein and neurofilament light chain as biomarkers of retinal neurodysfunction in early diabetic retinopathy: results of the EUROCONDOR study.
    Hernández C; Simó-Servat O; Porta M; Grauslund J; Harding SP; Frydkjaer-Olsen U; García-Arumí J; Ribeiro L; Scanlon P; Cunha-Vaz J; Simó R;
    Acta Diabetol; 2023 Jun; 60(6):837-844. PubMed ID: 36959506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment.
    Mazzeo S; Ingannato A; Giacomucci G; Bagnoli S; Cavaliere A; Moschini V; Balestrini J; Morinelli C; Galdo G; Emiliani F; Piazzesi D; Crucitti C; Frigerio D; Polito C; Berti V; Padiglioni S; Sorbi S; Nacmias B; Bessi V
    Neurol Sci; 2024 Mar; 45(3):1031-1039. PubMed ID: 37723371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurofilament light, glial fibrillary acidic protein, and tau in a regional epilepsy cohort: High plasma levels are rare but related to seizures.
    Akel S; Asztely F; Banote RK; Axelsson M; Zetterberg H; Zelano J
    Epilepsia; 2023 Oct; 64(10):2690-2700. PubMed ID: 37469165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association of serum neurofilament light chains with early symptoms related to Parkinson's disease: A cross-sectional study.
    Wang X; Yang X; He W; Song X; Zhang G; Niu P; Chen T
    J Affect Disord; 2023 Dec; 343():144-152. PubMed ID: 37805158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease.
    Pilotto A; Imarisio A; Conforti F; Scalvini A; Masciocchi S; Nocivelli S; Turrone R; Gipponi S; Cottini E; Borroni B; Rizzetti MC; Pizzi M; Bonanni L; Sturchio A; Espay AJ; Zetterberg H; Ashton NJ; Hye A; Padovani A
    Parkinsonism Relat Disord; 2021 Jun; 87():41-47. PubMed ID: 33964785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.